References
  1. Kahan SI. Practical strategies for engaging individuals with obesity in primary care. Mayo Clinic Proc. 2018;93(3):351-359.
  2. Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic treatment of overweight and obesity in adults. [Updated August 20, 2024] In: Feingold KR, Anawalt B, Blackman MR, et al., Eds. Endotext [Internet] MDText.com, Inc.; 2000-. PMID: 25905267. https://www.ncbi.nlm.nih.gov/books/NBK279038/
  3. Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Anti-obesity medication use in 2.2 million adults across 8 large healthcare organizations: 2009-2015. Obesity (Silver Spring). 2019;27(12):1975-1981.
  4. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
  5. Fox M. The weight of obesity and the role of the family physician. April 28, 2023. Accessed January 8, 2025. https://acofp.net/2023/04/28/the-weight-of-obesity-and-the-role-of-the-family-physician
  6. Alberga AS, Edache IY, Forhan M, Russell-Mayhew S. Weight bias and health care utilization: a scoping review. Prim Health Care Res Dev. 2019;20:e116.
  7. Puhl R, Peterson JL, Luedicke J. Motivating or stigmatizing? Public perceptions of weight-related language used by health providers. Int J Obes (Lond). 2013;37(4):612-619.
  8. Nadolsky K, Addison B, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severity. Endocr Pract. 2023;29(6):417-427.
  9. Oshman L, Othman A, Furst W, et al. Primary care providers' perceived barriers to obesity treatment and opportunities for improvement: a mixed methods study. PLoS One. 2023;18(4):e0284474
  10. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care. 2025;48(suppl 1):S167-S180.
  11. Torti J, Luig T, Borowitz M, Johnson JA, Sharma AM, Campbell-Scherer DL. The 5As team patient study: patient perspectives on the role of primary care in obesity management. BMC Fam Pract. 2017;18(1):19.
  12. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254-266.
  13. Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. 
  14. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.
  15. Laddu D, Neeland IJ, Carnethon M, et al; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; and Council on Cardiovascular and Stroke Nursing. Implementation of obesity science into clinical practice: a scientific statement from the American Heart Association. Circulation. 2024;150(1):e7-e19.
  16. Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
  17. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.
  18. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641-651.
  19. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.
  20. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183-197.
  21. Xu D, Nair A, Sigston C, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovasc Ther. 2022;2022:6820377.
  22. Food and Drug Administration. Tirzepatide. Prescribing information. Revised February 2025. Accessed February 13, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
  23. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596-e646.
  24. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056-1064. 
  25. Gadde KM, Atkins KD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother. 2020;21(11):1319-1328.
  26. Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160-171.
  27. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(suppl 1):222S-225S. 
  28. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity (Silver Spring). 2018;26(1):61-69.
  29. Knuth ND, Johannsen DL, Tamboli RA, et al. Metabolic adaptation following massive weight loss is related to the degree of energy imbalance and changes in circulating leptin. Obesity (Silver Spring). 2014;22(12):2563-2569.
  30. United States Government Accountability Office. Obesity Drugs: Few Adults Used Prescription Drugs for Weight Loss and Insurance Coverage Varied. Report to Congressional Committees. Published August 9, 2019. Accessed February 13, 2025. https://www.gao.gov/products/gao-19-577